The Hibiscus Study is enrolling adults and adolescents 12 to 65 years old with a clinical diagnosis of SCD.

The Thrive-131 study will evaluate the safety and efficacy of an investigational therapy called inclacumab to decrease vaso-occlusive crises in participants with sickle cell disease.

The MOMENTUM study is determining if an investigational gene therapy allows the body to produce more fetal hemoglobin.

To identify treatments that do not rely only on opioids or other medications.